AKTIEN IM FOKUS: Übernahme von Aetna setzen CVS-Health-Aktien unter Druck (Seite 7) | Diskussion im Forum
eröffnet am 05.03.18 21:49:56 von
neuester Beitrag 01.06.24 11:33:22 von
neuester Beitrag 01.06.24 11:33:22 von
Beiträge: 93
ID: 1.275.619
ID: 1.275.619
Aufrufe heute: 22
Gesamt: 10.392
Gesamt: 10.392
Aktive User: 0
ISIN: US1266501006 · WKN: 859034 · Symbol: CVS
57,43
EUR
+0,35 %
+0,20 EUR
Letzter Kurs 12:20:35 Tradegate
Neuigkeiten
| TitelBeiträge |
|---|
19.05.24 · wallstreetONLINE Redaktion |
10.05.24 · Business Wire (engl.)  |
03.05.24 · Business Wire (engl.) |
03.05.24 · Business Wire (engl.) |
Werte aus der Branche Einzelhandel
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,4600 | +47,31 | |
| 15,000 | +25,00 | |
| 50,00 | +24,97 | |
| 2,1100 | +14,05 | |
| 5,5250 | +12,99 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,5185 | -9,35 | |
| 23,460 | -11,04 | |
| 3,2100 | -11,08 | |
| 0,6400 | -14,67 | |
| 3,1000 | -20,51 |
Beitrag zu dieser Diskussion schreiben
Feedback
23.7.
How CVS Makes its Money
https://www.investopedia.com/articles/markets/012315/how-cvs…
...
The Bottom Line
Americans allegedly love freedom and football, but the true national pastime is consuming pharmaceuticals.
Everything from anxiety to restless legs syndrome now has a corresponding pill or injection to alleviate or eradicate the symptoms, and companies like CVS are at the forefront of getting those drugs to users. With the number of medical conditions being newly identified consistently outpacing those being eradicated, the amount of money spent on pharmaceuticals will likely increase—a development that should be resonant music to CVS shareholders.
How CVS Makes its Money
https://www.investopedia.com/articles/markets/012315/how-cvs…
...
The Bottom Line
Americans allegedly love freedom and football, but the true national pastime is consuming pharmaceuticals.
Everything from anxiety to restless legs syndrome now has a corresponding pill or injection to alleviate or eradicate the symptoms, and companies like CVS are at the forefront of getting those drugs to users. With the number of medical conditions being newly identified consistently outpacing those being eradicated, the amount of money spent on pharmaceuticals will likely increase—a development that should be resonant music to CVS shareholders.
CVS begins clinical trials for home-dialysis device
17.7.https://www.marketwatch.com/story/cvs-begins-clinical-trials…
=>
...CVS Health Corp. is making an ambitious move into kidney care, launching a clinical trial for a new home-dialysis device designed by the firm of Dean Kamen, the Segway inventor.
The company is delving into unusual territory for a drugstore and health insurer. The plan will make it a medical-device firm and a provider of dialysis, the complex blood-cleansing procedure vital to patients suffering from kidney failure. CVS holds exclusive U.S. rights to the HemoCare device, which was created by Mr. Kamen’s firm, Deka Research & Development Corp.
CVS will work to capitalize on an initiative announced last week by the Trump administration, which wants to move more dialysis into the home, rather than dialysis centers, where most U.S. patients currently get the procedure.
Dialysis is covered by Medicare, including for patients under the age of 65. The care of patients with end-stage renal disease is a major cost for the program, amounting to around $35 billion in 2016, or roughly 7% of total spending under traditional Medicare.
The Department of Health and Human Services said increased use of home dialysis could reduce costs and “preserve or enhance the quality of care.”...
!
Dieser Beitrag wurde von MadMod moderiert. Grund: bitte jetzt nicht Eigenwerbung übertreiben
Antwort auf Beitrag Nr.: 60.467.324 von faultcode am 02.05.19 00:43:25
https://www.marketwatch.com/story/stocks-of-drug-distributor…
=>
...Shares of drug distributors and pharmacy-benefit-manager owners got a boost on Thursday after the Trump administration said it would be withdrawing its plan to overhaul the rebates that drugmakers give to middlemen in Medicare.
The administration, which is making lowering drug costs for Americans a key priority, had said such a proposal would help drive down the prices people pay for prescription medications. However, that would have been a blow to drug distributors and pharmacy-benefit managers, or PBMs.
PBMs act as middlemen between drugmakers and insurance plans, negotiating discounted prices on branded prescription drugs in the form of a rebate. However, PBMs end up pocketing some of those rebates for themselves. The proposal looked to direct those discounts toward patients instead.
“The rule has been an overhang for... stocks for well over a year,” Evercore ISI’s Ross Muken wrote in a note to clients. “Its withdrawal is positive news for companies in the drug channel with economics tied to higher gross list prices, including PBMs and their parent companies, distributors and pharmacies.”
...
The pulling of the proposal comes after a federal judge on Monday blocked a plan put forth by the Trump administration requiring drugmakers to disclose their drug prices in television ads. It was another part of the president’s plan to lower drug costs.
The administration is still looking at ways to lower those costs. Just last week, the president said he was planning to issue an executive order allowing the U.S. to buy drugs based on the lowest price paid by other developed countries.
Stocks of drug distributors and PBM-owners surge after Trump administration pulls rebate proposal
July 11, 2019 10:42 a.m. EThttps://www.marketwatch.com/story/stocks-of-drug-distributor…
=>
...Shares of drug distributors and pharmacy-benefit-manager owners got a boost on Thursday after the Trump administration said it would be withdrawing its plan to overhaul the rebates that drugmakers give to middlemen in Medicare.
The administration, which is making lowering drug costs for Americans a key priority, had said such a proposal would help drive down the prices people pay for prescription medications. However, that would have been a blow to drug distributors and pharmacy-benefit managers, or PBMs.
PBMs act as middlemen between drugmakers and insurance plans, negotiating discounted prices on branded prescription drugs in the form of a rebate. However, PBMs end up pocketing some of those rebates for themselves. The proposal looked to direct those discounts toward patients instead.
“The rule has been an overhang for... stocks for well over a year,” Evercore ISI’s Ross Muken wrote in a note to clients. “Its withdrawal is positive news for companies in the drug channel with economics tied to higher gross list prices, including PBMs and their parent companies, distributors and pharmacies.”
...
The pulling of the proposal comes after a federal judge on Monday blocked a plan put forth by the Trump administration requiring drugmakers to disclose their drug prices in television ads. It was another part of the president’s plan to lower drug costs.
The administration is still looking at ways to lower those costs. Just last week, the president said he was planning to issue an executive order allowing the U.S. to buy drugs based on the lowest price paid by other developed countries.
Strong Buy wenn Notenbank Zins senkt wegen Handelsstreik imo
Trading Spotlight
FDA Under Pressure, New CBD Rules to be Announced on Friday
https://www.thecannabisinvestor.ca/fda-under-pressure-new-cb… Big-Box Retailers Walmart and Target Could be Set to Enter the CBD Frenzy
https://www.thecannabisinvestor.ca/big-box-retailers-walmart… CVS Health raises full-year profit forecast on Aetna strength
1.5.https://finance.yahoo.com/news/cvs-health-beats-profit-estim…
=>
...CVS Health Corp on Wednesday raised its full-year profit forecast and reported first-quarter earnings that topped Wall Street estimates due to growth in its Aetna health insurance business, and as drug prices fell within its expectations.
Shares rose more than 5 percent to $57.35. They had fallen 17 percent this year, hurt by a weak forecast in February and a cut to rival Walgreen Boots Alliance's full-year outlook last month due to lower generic drug prices.
Aetna, CVS's health insurance unit, beat analysts' consensus by more than a billion dollars in the quarter, helped by its accounting for lower medical costs than anticipated during the fourth quarter.
The company, which bought Aetna for $69 billion in November, said 2019 cost savings from the deal were tracking near the high end of its $300 million to $350 million range, and that 2020 savings would likely exceed its $750 million target...
CVS and Walgreens to Sell CBD Products Despite the FDA’s Growing Concerns
https://www.thecannabisinvestor.ca/cvs-and-walgreens-to-sell…
Update Die planen nicht sondern es ist bereits soweit. Bis zum heutigen Tage werden insgesamt 800 Apotheken mit der Ware beliefert. https://www.investopedia.com/cvs-selling-cbd-products-curale…
Durchsuchen
19.05.24 · wallstreetONLINE Redaktion · Amazon |
02.05.24 · wO Chartvergleich · Ansys |
01.05.24 · wallstreetONLINE Redaktion · CVS Health |
01.05.24 · dpa-AFX · Advanced Micro Devices |
23.04.24 · Aktienwelt360 · Chevron Corporation |
16.04.24 · dpa-AFX · CVS Health |